VC  Foresite Capital

http://www.foresitecapital.com





     Office Locations:

101 California Street
Suite 4100
San Francisco, CA 94111
Phone: 415-877-4887
Fax: 415-567-0091

Get all office locations for this firm with a National Database subscription or New York Database subscription.
 

Stages:

  • Expansion


 

Industries:

  • Life Sciences & Healthcare
  • Medical Device

  •  

    Description:

    Foresite Capital invests between $10 million and $50 million per investment in healthcare companies with disruptive late-stage products with large market opportunities across all healthcare sectors. Since inception in 2011, Foresite has invested in 11 transformative companies spanning therapeutics, devices and diagnostics. In April of 2014, the firm announced the closing of Foresite Capital Fund II, which was oversubscribed and closed with $300 million in capital commitments. Fund II follows Foresite Capital Fund I, a $100 million fund that closed in January 2013.


     

    Funds:


      Fund Name


      Amount


      Date

    Get funds under management for this firm including Fund name, Dollar size of fund raise, and Vintage with a National Database subscription or New York Database subscription.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or New York Database subscription.
    Christine Aylward Managing Director
    Dennis D. Ryan CFO & Managing Director
    Dorothy Margolskee Managing Director
    James Tananbaum CEO & Managing Director
    Matthew Buten Managing Director

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      09/18/2017


      LifeMine Therapeutics


      MA


      $55,000,000


      Series A


      09/08/2017


      Replimune


      MA


      $55,000,000


      Series B


      07/26/2017


      VenatoRx Pharmaceuticals


      PA


      $42,000,000


      Series B


      06/15/2017


      Mindstrong Health


      CA


      $14,000,000


      Series A


      03/01/2017


      Muse Bio


      CO


      $23,000,000


      Series B


     

    Portfolio companies include:


      10X Genomics
        web link


      AcelRx Pharmaceuticals
        web link


      Aduro BioTech
        web link


      Ambit Biosciences
        web link


      Arcus Biosciences
        web link


      AveXis
        web link


      Intarcia Therapeutics
        web link


      Intellia Therapeutics
        web link


      Ivantis
        web link


      Jounce Therapeutics
        web link


      Karyopharm Therapeutics
        web link


      Keryx Biopharmaceuticals
        web link


      LifeMine Therapeutics
        web link


      Mindstrong Health
        web link


      Muse Bio
        web link


      ORIC Pharmaceuticals
        web link


      Peloton Therapeutics
        web link


      Puma Biotechnology
        web link


      REGENXBIO
        web link


      Replimune
        web link


      Sequenta
        web link


      Tarsa Therapeutics
        web link


      VenatoRx Pharmaceuticals
        web link


      WaVe Life Sciences
        web link


      WaveTec Vision Systems
        web link


     

    Recent News: